v3.8.0.1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2018
Mar. 31, 2017
NET REVENUE    
Clinical testing $ 56,971 $ 52,907
Pharma Services 6,452 4,521
Total Revenue 63,423 57,428
COST OF REVENUE 36,120 34,480
GROSS PROFIT 27,303 22,948
Operating expenses:    
General and administrative 17,067 17,018
Research and development 956 862
Sales and marketing 6,775 5,648
Total operating expenses 24,798 23,528
INCOME (LOSS) FROM OPERATIONS 2,505 (580)
Interest expense, net 1,486 1,364
Other income (63) 0
Income (loss) before taxes 1,082 (1,944)
Income tax (benefit) expense 438 (779)
NET INCOME (LOSS) 644 (1,165)
Deemed dividends on preferred stock 1,003 894
Amortization of preferred stock beneficial conversion feature 1,853 1,672
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS $ (2,212) $ (3,731)
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS    
Basic (in dollars per share) $ (0.03) $ (0.05)
Diluted (in dollars per share) $ (0.03) $ (0.05)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:    
Basic (in shares) 80,507 78,650
Diluted (in shares) 80,507 78,650

Source